Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer

Ann Oncol. 2012 Sep;23(9):2470-2471. doi: 10.1093/annonc/mds249.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters / genetics
  • Alanine Transaminase / blood*
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / pharmacology*
  • Anticholesteremic Agents / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Chemical and Drug Induced Liver Injury / epidemiology
  • Chemical and Drug Induced Liver Injury / genetics
  • Clinical Trials as Topic
  • Drug Interactions
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy
  • Incidence
  • Indazoles
  • Neoplasm Proteins / genetics
  • Neoplasms / blood*
  • Neoplasms / drug therapy
  • Polymorphism, Single Nucleotide
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Reference Values
  • Simvastatin / adverse effects
  • Simvastatin / pharmacology*
  • Simvastatin / therapeutic use
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use

Substances

  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters
  • Anticholesteremic Agents
  • Antineoplastic Agents
  • Indazoles
  • Neoplasm Proteins
  • Pyrimidines
  • Sulfonamides
  • pazopanib
  • Simvastatin
  • Alanine Transaminase